Click here to close now.




















Welcome!

News Feed Item

PDS Biotechnology Announces Treatment of First Patient with PDS0101 based on the Novel Versamune™ Cancer Immunotherapy Platform in a Phase 1 Clinical Trial

NORTH BRUNSWICK, N.J., Feb. 11, 2014 /PRNewswire/ -- PDS Biotechnology Corp., a clinical-stage biotechnology company focused on the development of novel immunotherapy treatments for cancer and other chronic diseases, as well as novel preventive vaccines, today announced that the first patient has been successfully vaccinated with PDS0101 in a Phase 1 clinical trial in patients with cervical intraepithelial neoplasia.

The trial which is being conducted at three leading gynecological oncology centers in the United States is designed to evaluate the safety, feasibility and immunological responses of the novel Versamune-based PDS0101 cancer immunotherapy in patients with cervical intraepithelial neoplasia.

"The ability to effectively train and prime our body's immune system to specifically target and kill cancer cells has recently shown significant promise in treating various cancers," said Dr. Frank Bedu-Addo, CEO of PDS Biotechnology.  "Should the unique safety profile and efficacy of Versamune and PDS0101 demonstrated in preclinical studies be successfully replicated in humans, this will represent a significant advancement in the treatment of cancer. It would also represent a significant advancement in the treatment of early-stage cancer and certain infectious diseases where there is a high and growing unmet medical need not addressed by current approaches."

About PDS Biotechnology Corporation
PDS Biotechnology is a private biotechnology company applying its ground-breaking Versamune nanotechnology platform vector to the development of simpler, safer and more effective cancer immunotherapies and preventive vaccines.  PDS0101 is the company's lead cancer immunotherapy in development to treat HPV-induced cancers.  The company has a second cancer immunotherapy and pandemic influenza vaccine in the early stages of development. In 2012 PDS Biotechnology granted Merck KGaA a license to utilize the Versamune vector in two specific cancer immunotherapies.  For more information on PDS biotechnology please visit www.pdsbiotech.com.

About Versamune and PDS0101
PDS0101 is a cancer immunotherapy based on PDS Biotechnology's patented Versamune nanotechnology vector, and contains multiple unique sequences from a cancer causing strain of the human papillomavirus that have been modified to be more immunogenic.  

Versamune is based on certain structurally-specific lipids which possess unique immune modulating characteristics.  In preclinical studies Versamune was demonstrated to facilitate uptake and processing of the cancer proteins by the immune system.  It also enhanced successful priming and training of cancer-killing T-cells, and simultaneously reduced the population of immune suppressive cells leading to superior efficacy in eradicating the cancer in preclinical studies.  For more information on Versamune and how it works please visit www.pdsbiotech.com.

Cancers Caused by the Human papillomavirus
Patients diagnosed with the various HPV-induced cancers such as today have very limited treatment options, predominantly surgery, chemotherapy and radiation therapy.

Cervical intraepithelial neoplasia (CIN) is the abnormal growth of cells on the cervix.  A small percentage of CIN cases progress to become cervical cancer if left untreated.  The annual worldwide incidence is about 1.4 million.  The current treatment for high grade CIN involves removal of the cervical cells by methods such as loop electrical excision procedure (LEEP). The recurrence rate is reportedly about 20%, and surgical treatment is associated with an increased risk of infertility.

Oropharyngeal squamous cell carcinoma (OSCC): Over 70% of OSCC are estimated to be HPV-associated in Western countries.  It is predicted that the incidences of HPV-positive oral cancers will exceed the annual number of cervical cancer cases by 2020.

Cervical Cancer: It was estimated that in the US there would be over 12,000 newly diagnosed cases of cervical cancer in 2013.

SOURCE PDS Biotechnology Corporation

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Explosive growth in connected devices. Enormous amounts of data for collection and analysis. Critical use of data for split-second decision making and actionable information. All three are factors in making the Internet of Things a reality. Yet, any one factor would have an IT organization pondering its infrastructure strategy. How should your organization enhance its IT framework to enable an Internet of Things implementation? In his session at @ThingsExpo, James Kirkland, Red Hat's Chief Arch...
Chuck Piluso presented a study of cloud adoption trends and the power and flexibility of IBM Power and Pureflex cloud solutions. Prior to Secure Infrastructure and Services, Mr. Piluso founded North American Telecommunication Corporation, a facilities-based Competitive Local Exchange Carrier licensed by the Public Service Commission in 10 states, serving as the company's chairman and president from 1997 to 2000. Between 1990 and 1997, Mr. Piluso served as chairman & founder of International Te...
It is one thing to build single industrial IoT applications, but what will it take to build the Smart Cities and truly society-changing applications of the future? The technology won’t be the problem, it will be the number of parties that need to work together and be aligned in their motivation to succeed. In his session at @ThingsExpo, Jason Mondanaro, Director, Product Management at Metanga, discussed how you can plan to cooperate, partner, and form lasting all-star teams to change the world...
The Internet of Everything (IoE) brings together people, process, data and things to make networked connections more relevant and valuable than ever before – transforming information into knowledge and knowledge into wisdom. IoE creates new capabilities, richer experiences, and unprecedented opportunities to improve business and government operations, decision making and mission support capabilities.
Public Cloud IaaS started its life in the developer and startup communities and has grown rapidly to a $20B+ industry, but it still pales in comparison to how much is spent worldwide on IT: $3.6 trillion. In fact, there are 8.6 million data centers worldwide, the reality is many small and medium sized business have server closets and colocation footprints filled with servers and storage gear. While on-premise environment virtualization may have peaked at 75%, the Public Cloud has lagged in adop...
How do you securely enable access to your applications in AWS without exposing any attack surfaces? The answer is usually very complicated because application environments morph over time in response to growing requirements from your employee base, your partners and your customers. In his session at @DevOpsSummit, Haseeb Budhani, CEO and Co-founder of Soha, shared five common approaches that DevOps teams follow to secure access to applications deployed in AWS, Azure, etc., and the friction an...
SYS-CON Events announced today that MobiDev, a software development company, will exhibit at the 17th International Cloud Expo®, which will take place November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. MobiDev is a software development company with representative offices in Atlanta (US), Sheffield (UK) and Würzburg (Germany); and development centers in Ukraine. Since 2009 it has grown from a small group of passionate engineers and business managers to a full-scale mobi...
Digital Transformation is the ultimate goal of cloud computing and related initiatives. The phrase is certainly not a precise one, and as subject to hand-waving and distortion as any high-falutin' terminology in the world of information technology. Yet it is an excellent choice of words to describe what enterprise IT—and by extension, organizations in general—should be working to achieve. Digital Transformation means: handling all the data types being found and created in the organizat...
The Software Defined Data Center (SDDC), which enables organizations to seamlessly run in a hybrid cloud model (public + private cloud), is here to stay. IDC estimates that the software-defined networking market will be valued at $3.7 billion by 2016. Security is a key component and benefit of the SDDC, and offers an opportunity to build security 'from the ground up' and weave it into the environment from day one. In his session at 16th Cloud Expo, Reuven Harrison, CTO and Co-Founder of Tufin,...
The Internet of Things is not only adding billions of sensors and billions of terabytes to the Internet. It is also forcing a fundamental change in the way we envision Information Technology. For the first time, more data is being created by devices at the edge of the Internet rather than from centralized systems. What does this mean for today's IT professional? In this Power Panel at @ThingsExpo, moderated by Conference Chair Roger Strukhoff, panelists addressed this very serious issue of pro...
Discussions about cloud computing are evolving into discussions about enterprise IT in general. As enterprises increasingly migrate toward their own unique clouds, new issues such as the use of containers and microservices emerge to keep things interesting. In this Power Panel at 16th Cloud Expo, moderated by Conference Chair Roger Strukhoff, panelists addressed the state of cloud computing today, and what enterprise IT professionals need to know about how the latest topics and trends affect t...
Containers are changing the security landscape for software development and deployment. As with any security solutions, security approaches that work for developers, operations personnel and security professionals is a requirement. In his session at DevOps Summit, Kevin Gilpin, CTO and Co-Founder of Conjur, will discuss various security considerations for container-based infrastructure and related DevOps workflows.
Countless business models have spawned from the IaaS industry. Resell Web hosting, blogs, public cloud, and on and on. With the overwhelming amount of tools available to us, it's sometimes easy to overlook that many of them are just new skins of resources we've had for a long time. In his General Session at 16th Cloud Expo, Phil Jackson, Lead Technology Evangelist at SoftLayer, broke down what we've got to work with and discuss the benefits and pitfalls to discover how we can best use them to d...
The essence of cloud computing is that all consumable IT resources are delivered as services. In his session at 15th Cloud Expo, Yung Chou, Technology Evangelist at Microsoft, demonstrated the concepts and implementations of two important cloud computing deliveries: Infrastructure as a Service (IaaS) and Platform as a Service (PaaS). He discussed from business and technical viewpoints what exactly they are, why we care, how they are different and in what ways, and the strategies for IT to tran...
Puppet Labs has announced the next major update to its flagship product: Puppet Enterprise 2015.2. This release includes new features providing DevOps teams with clarity, simplicity and additional management capabilities, including an all-new user interface, an interactive graph for visualizing infrastructure code, a new unified agent and broader infrastructure support.